Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of three oral doses of S44121 on exercise-induced arrhythmias in CPVT type 1
2009-011560-11Phase 2Completed
- Sponsor
- Servier
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of S44121 in catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1) and polymorphic ventricular tachycardia (PVT) (3 arms), sponsored by Servier. Primary endpoint: Cardiac arrhythmias during standardised exercise tests. Started Nov 2009; status: completed.
02
Drugs
S44121
03
Conditions
catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1)polymorphic ventricular tachycardia (PVT)
Beyond the preview
Go deeper on 2009-011560-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011560-11.